Paper Details 
Original Abstract of the Article :
BACKGROUND: Pimavanserin prolongs the QT interval, with mean increases in corrected QT (QTc) of 5-8 ms, and is currently being investigated for the treatment of negative symptoms of schizophrenia. OBJECTIVES: To assess QT interval prolongation in 3 studies investigating once-daily pimavanserin as a...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486460/

データ提供:米国国立医学図書館(NLM)

Investigating the Effects of Pimavanserin on QT Interval Prolongation in Schizophrenia

The world of medicine is a vast desert, full of mysteries waiting to be uncovered. One such mystery involves the treatment of schizophrenia. This research delves into the effects of pimavanserin, a medication with the potential to address the negative symptoms of schizophrenia, on a crucial aspect of heart health: the QT interval. This study, like a skilled navigator traversing a sandstorm, carefully examines the impact of pimavanserin on the QT interval in patients with schizophrenia, comparing its effects to those of a placebo. The researchers meticulously analyzed electrocardiograms from three clinical trials, each with a unique duration, to gather insights into the potential for QT prolongation.

Adjunctive Pimavanserin Shows No Evidence of QT Prolongation

The findings paint a reassuring picture. The researchers discovered that when pimavanserin was used as an adjunct to existing antipsychotic treatment, it did not cause a significant prolongation of the QT interval. This is good news, as a prolonged QT interval can be associated with serious heart rhythm problems. The results are consistent with earlier reports on pimavanserin's effects on the QT interval, providing further evidence of its potential safety profile.

Implications for Schizophrenia Treatment

This study provides valuable information for physicians and researchers, shedding light on the potential benefits of pimavanserin in treating schizophrenia while also ensuring the safety of patients' hearts. With this knowledge, physicians can better guide treatment strategies for patients with schizophrenia, ensuring that they receive effective care while minimizing any potential cardiac risks.

Dr. Camel's Conclusion

This study is like an oasis in the desert of schizophrenia research, offering a glimmer of hope for patients suffering from this complex condition. It highlights the importance of meticulous research, like a careful expedition across shifting sands, to uncover the secrets of effective and safe treatment options.

Date :
  1. Date Completed n.d.
  2. Date Revised 2022-09-24
Further Info :

Pubmed ID

36147980

DOI: Digital Object Identifier

PMC9486460

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.